Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanoma

BACKGROUND: The indoleamine 2,3-dioxygenase (IDO) pathway is a key counter-regulatory mechanism that, in cancer, is exploited by tumors to evade antitumor immunity. Indoximod is a small-molecule IDO pathway inhibitor that reverses the immunosuppressive effects of low tryptophan (Trp) and high kynure...

Descripción completa

Detalles Bibliográficos
Autores principales: Zakharia, Yousef, McWilliams, Robert R, Rixe, Olivier, Drabick, Joseph, Shaheen, Montaser F, Grossmann, Kenneth F, Kolhe, Ravindra, Pacholczyk, Rafal, Sadek, Ramses, Tennant, Lucinda L, Smith, Christopher M, Kennedy, Eugene P, Link Jr, Charles J, Vahanian, Nicholas N, Yu, Jiayi, Shen, Steven S, Brincks, Erik L, Rossi, Gabriela R, Munn, David, Milhem, Mohammed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8202104/
https://www.ncbi.nlm.nih.gov/pubmed/34117113
http://dx.doi.org/10.1136/jitc-2020-002057

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8202104/
https://www.ncbi.nlm.nih.gov/pubmed/34117113
http://dx.doi.org/10.1136/jitc-2020-002057

Ejemplares similares